Plus   Neg

Incyte To Present Updated Results From Ongoing Phase II Trial of INCB18424 At American Society of Hematology Annual Meeting - Quick Facts

Saturday, Incyte Corp. (INCY) said it would present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase or JAK inhibitor, in patients with myelofibrosis at the 50th American Society of Hematology Annual Meeting. The company intends to describe the most current data from the ongoing Phase II trial in four posters to be presented at the meeting

The company said the updated data set confirms that long term INCB18424 treatment has been well tolerated and results in durable clinical improvement in splenomegaly, constitutional symptoms and cachexia. New data also demonstrate improvement in exercise tolerance and confirmation of spleen size reduction as measured by MRI.

Study INCB18424-251 is an ongoing Phase II trial in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis with both mutated JAK2 or V617F mutation and normal JAK2 or wild type. Primary objectives of the study include the determination of the safety and efficacy of INCB18424 treatment in MF patients, evaluation of twice-daily and once-daily dosing regimens to identify an optimal dosing paradigm for use in future clinical trials and prospective identification of functional measures of clinical efficacy.

For comments and feedback contact: editorial@rttnews.com

Follow RTT